Newborns and infants are at risk of infection and respond sub-optimally to vaccines due in part to impaired Th1-polarizing responses of antigen-presenting cells and lymphocytes. Characterization of the underlying mechanisms may identify novel approaches to neonatal immunization. We have shown that neonatal blood plasma has higher concentrations of adenosine (Ado), an endogenous purine metabolite that acts via Ado receptors to increase cytosolic cyclic Ado mono-phosphate (cAMP) and thereby impairs Th1-polarizing immune responses. Neonatal plasma contains high concentrations of Ado-generating alkaline phosphatase (AP) and 5'ectonucleotidase CD73 while containing less Ado deaminase (ADA) than adult plasma, resulting in higher Ado concentrations at birth. Monocyte (Mo)-derived dendritic cells (MoDCs) are sensitive to Ado inhibition and express cell-associated Ado-generating (CD73) and metabolizing (ADA) enzymes. To better simulate endogenous Ado-based regulation of neonatal immune responses, we have developed an autologous three-dimensional neonatal tissue construct (NTC) and a corresponding adult tissue construct (ATC), comprised of extracellular matrix, autologous plasma, and an overlying endothelium upon which cryopreserved cord blood- or peripheral blood-mononuclear cells or CD33-selected Mos extravasate and autonomous MoDC development and activation can be studied. The project objective is to characterize the impact of neonatal purine metabolism on immune responses to adjuvants, including Toll-like receptor (TLR) agonists, and vaccines, by pursuing the following Specific Aims:
In Aim 1, we will assess the relative contribution of AP, CD73 and ADA to Ado accumulation in human neonatal vs. adult blood plasma. We will employ thin layer chromatography, pharmacologic inhibitors, enzyme immunodepletion, and high performance liquid chromatography. The ontogeny of purine-metabolizing enzymes will be characterized using neonatal and infant plasma samples.
In Aim 2, we will determine effects of soluble and cell-associated AP, CD73 and ADA on activation of autonomously generated MoDCs. We will employ the novel NTC, interrogating the ability of adjuvants and vaccines, such as Bacillus Calmette-Guerin (BCG), hepatitis B vaccine, and pneumoccal conjugate vaccine to induce ADA, modulate Ado levels, and trigger differentiation and activation of mature MoDCs as measured by migration, up-regulation of co-stimulatory molecules, and induction of Th1/Th2/Th17- polarizing cytokines.
In Aim 3, we will characterize enhancing effects of Ado-refractory adjuvants, TLR8 agonists and ADA, on Ag-specific neonatal vaccine responses in vitro. We will employ co-culture of NTC-derived MoDCs and autologous lymphocytes in vaccine antigen prime, boost, and challenge assays using the NTC. These studies will provide insight into neonatal immunity, establish novel platforms for studying immune ontogeny, assess Ado-refractory adjuvants, and inform neonatal vaccine development.
Over 2,000,000 newborns and young infants die due to infection every year, in part due to their relatively weak immune responses. Our project makes use of blood components to model immune responses of newborns and infants to vaccines. By studying mechanisms and factors that impair immune responses early in life, we hope to identify more effective ways to immunize newborns, thereby protecting them from infection and enhancing public health.
|Scheid, Annette; Borriello, Francesco; Pietrasanta, Carlo et al. (2018) Adjuvant Effect of Bacille Calmette-Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. Front Immunol 9:29|
|Borriello, Francesco; van Haren, Simon D; Levy, Ofer (2018) First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines. mSphere 3:|
|Schüller, Simone S; Kramer, Boris W; Villamor, Eduardo et al. (2018) Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future. Front Pediatr 6:199|
|Borriello, Francesco; Pietrasanta, Carlo; Lai, Jacqueline C Y et al. (2017) Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. Front Immunol 8:1772|
|Dowling, David J; Scott, Evan A; Scheid, Annette et al. (2017) Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol 140:1339-1350|
|van Haren, Simon D; Ganapathi, Lakshmi; Bergelson, Ilana et al. (2016) In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine 83:99-109|
|Pettengill, Matthew Aaron; Levy, Ofer (2016) Circulating Human Neonatal Naïve B Cells are Deficient in CD73 Impairing Purine Salvage. Front Immunol 7:121|
|Pettengill, Matthew A; van Haren, Simon D; Li, Ning et al. (2016) Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naïve B cells. Innate Immun 22:433-43|
|Goodridge, Helen S; Ahmed, S Sohail; Curtis, Nigel et al. (2016) Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 16:392-400|
|Fish, Eleanor N; Flanagan, Kate L; Furman, David et al. (2016) Changing oral vaccine to inactivated polio vaccine might increase mortality. Lancet 387:1054-1055|
Showing the most recent 10 out of 31 publications